Program
Filgrastim
Also written as “filgrastim”, “Neupogen (filgrastim)” and “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”.
Its studies are mostly in Neutropenia · Breast Neoplasms · ST Elevation Myocardial Infarction · Multiple Myeloma · Lymphoma, Non-Hodgkin, led by 15 companies.
Drug pageFilgrastim: every studyMany companies study it; this page follows only the 27 they lead. All 304 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 50 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pfizerits history only | 50 open or running | phase 2since Nov 5, 2013 | Nov 5, 2013 | none ahead |
| Biocadits history only | 30 open or running | phase 3since Apr 2, 2014 | Mar 30, 2012 | none ahead |
| Dong-A STits history only | 20 open or running | phase 3since Nov 10, 2017 | Mar 22, 2016 | none ahead |
| Novartisits history only | 20 open or running | phase 4since May 8, 2013 | Jan 13, 2012 | none ahead |
| Axaron Bioscienceits history only | 10 open or running | phase 2since Aug 18, 2005 | Aug 18, 2005 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Mar 6, 2012 | Mar 6, 2012 | none ahead |
| BioGeneric Pharmaits history only | 11 open or running | phase 1since Oct 4, 2026 | Oct 4, 2026 | Apr 7, 2027phase 1 · NCT07877467 |
| Clinique Ovoits history only | 10 open or running | phase 3since Mar 19, 2014 | Mar 19, 2014 | none ahead |
| CSLits history only | 10 open or running | phase 1since May 31, 2019 | May 31, 2019 | none ahead |
| Dong-A Pharmaceuticalits history only | 10 open or running | phase 1since Mar 15, 2013 | Mar 15, 2013 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Mar 2, 2010 | Mar 2, 2010 | none ahead |
| Hangzhou Jiuyuan Gene Engineeringits history only | 10 open or running | phase 2since Aug 6, 2013 | Aug 6, 2013 | none ahead |
| Proteonomixits history only | 10 open or running | phase 1since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| Sygnis Bioscience GmbH & Co KGits history only | 10 open or running | phase 2since Jun 24, 2009 | Jun 24, 2009 | none ahead |
Also a collaborator on its studies: Celerion, Sandoz and Numoda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Nov 2, 1999.
- Mar 15, 2013Dong-A Pharmaceutical’s first study: phase 1 study in Diabetic NeuropathiesNew to Dong-A PharmaceuticalDong-A Pharmaceutical · NCT01820715 · 31 enrolled · Korea, Republic of
- May 8, 2013Phase 4 study in Neutropenia, severe chronicNovartis · NCT01859637 · 6 enrolled · Germany, Sweden
- Aug 6, 2013Hangzhou Jiuyuan Gene Engineering’s first study: phase 2 study in NeutropeniaNew to Hangzhou Jiuyuan Gene EngineeringHangzhou Jiuyuan Gene Engineering · NCT01918241 · 200 enrolled · China
- Nov 5, 2013Pfizer’s first study: phase 2 study in Advanced Multiple MyelomaNew to PfizerPfizer · NCT01989325 · 77 enrolled · United States
- Mar 19, 2014Clinique Ovo’s first study: phase 3 study in InfertilityNew to Clinique OvoClinique Ovo · NCT02149277 · 15 enrolled · Canada
- Mar 19, 2014Phase 2 study in Advanced Multiple MyelomaPfizer · NCT02092922 · 154 enrolled · United States, Belgium, Canada and more
- Apr 2, 2014Phase 3 study in NeutropeniaBiocad · NCT02104830 · 135 enrolled · Russian Federation
- Mar 22, 2016Dong-A ST’s first study: phase 1 study in HealthyNew to Dong-A STDong-A ST · NCT02725086 · 56 enrolled · Korea, Republic of
- Apr 1, 2016Phase 1 study in LeukocytosisBiocad · NCT02762799 · 60 enrolled
- May 6, 20162 phase 1 studies in NeutropeniaPfizer · NCT02766647, NCT02766634
- Sep 30, 2016Phase 1 study in Healthy VolunteersPfizer · NCT02923791 · 256 enrolled · United States
- Nov 10, 2017Phase 3 study in Breast NeoplasmsDong-A ST · NCT03343145 · 143 enrolled · Indonesia
- May 31, 2019CSL’s first study: phase 1 study in Hidradenitis SuppurativaNew to CSLCSL · NCT03972280 · 39 enrolled · Australia, Denmark, Germany
- Oct 4, 2026BioGeneric Pharma’s first study: phase 1 study in NeutropeniaNew to BioGeneric PharmaBioGeneric Pharma · NCT07877467 · 50 planned
Ahead
- Apr 7, 2027Primary completion: phase 1 study in NeutropeniaBioGeneric Pharma · NCT07877467
TargetBeta
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule
Other programs on CSF3R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pegfilgrastimrule | Amgen | phase 4 | 52 |
| anumigilimabrule | CSL | phase 2 | 4 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07877467Neutropenia | 1 | Not yet recruiting | BioGeneric Pharma | Apr 7, 2027 | 50 |
| NCT03972280Hidradenitis Suppurativa · Australia, Denmark, Germany | 1 | Completed | CSL | Oct 4, 2022 | 39 |
| NCT03343145Breast Neoplasms · Indonesia | 3 | Completed | Dong-A ST | Jan 28, 2019 | 143 |
| NCT02923791Healthy Volunteers · United States | 1 | Completed | Pfizer | Jan 2017 | 256 |
| NCT02766647Neutropenia · United States | 1 | Completed | Pfizer | Feb 2016 | 24 |
| NCT02766634Neutropenia · United States | 1 | Completed | Pfizer | Jun 2016 | 60 |
| NCT02762799Leukocytosis | 1 | Completed | Biocad | Nov 11, 2016 | 60 |
| NCT02725086Healthy · Korea, Republic of | 1 | Completed | Dong-A ST | Apr 2016 | 56 |
| NCT02104830Neutropenia · Russian Federation | 3 | Completed | Biocad | Jun 2014 | 135 |
| NCT02149277Infertility · Canada | 3 | Terminated | Clinique Ovo | Dec 2017 | 15 |
| NCT02092922Advanced Multiple Myeloma · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Jul 2016 | 154 |
| NCT01989325Advanced Multiple Myeloma · United States | 2 | Completed | Pfizer | Feb 2016 | 77 |
| NCT01918241Neutropenia · China | 2 | UNKNOWN | Hangzhou Jiuyuan Gene Engineering | Jan 2016 | 200 |
| NCT01859637Neutropenia, severe chronic · Germany, Sweden | 4 | Terminated | Novartis | Mar 2014 | 6 |
| NCT01820715Diabetic Neuropathies · Korea, Republic of | 1 | Completed | Dong-A Pharmaceutical | Apr 2013 | 31 |
| NCT01711073End Stage Liver Disease · United States | 1 | UNKNOWN | Proteonomix | Sep 2013 | 15 |
| NCT01569087Neutropenia · Russian Federation | 2 | Completed | Biocad | Jan 2013 | 60 |
| NCT01549301Healthy Subjects · Brazil | 1 | Completed | Azidus Brasil | Aug 2013 | 128 |
| NCT01519700Breast Neoplasms · Czech Republic, Hungary, Latvia and more | 3 | Completed | Novartis | Jun 2013 | 218 |
| NCT01079676Neutropenia in Breast Cancer · Brazil | 3 | Completed | Eurofarma Laboratorios | Apr 2011 | 220 |
| NCT00927836Ischemic Stroke · Austria, Belgium, Czech Republic and more | 2 | Completed | Sygnis Bioscience GmbH & Co KG | Nov 2011 | 328 |
| NCT00132470Stroke · Germany | 2 | Completed | Axaron Bioscience | 42 | |
| NCT00117897Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00117455Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00006215Lung Neoplasms · United States | 2 | UNKNOWN | Amgen | ||
| NCT00005958Urinary Bladder Neoplasms · United States | 2 | UNKNOWN | Amgen | ||
| NCT00002126HIV Infections · United States, Canada | 2 | Completed | Amgen | 250 |
How it is read
Names in the registry
- “Filgrastim”, 11 entries
- “filgrastim”, 4 entries
- “Neupogen (filgrastim)”, 2 entries
- “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
- “Leucostim®”, 2 entries
Codes read as this program: DA3030.
Conditions, from the studies’ own filings
- Neutropenia, 7 studies
- Breast Neoplasms, 3 studies
- ST Elevation Myocardial Infarction, 2 studies
- Multiple Myeloma, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.